Suppression of SARS replication by SARS helicase inhibitors

摘要

The present invention relates to compounds, compositions, and methods, for treating subjects suspected of needing treatment for a Nidovirales virus infection. In certain embodiments, the compounds comprise Nidovirales helicase inhibitors that do not significantly affect helicase ATPase enzymatic activity or nucleic acid binding activity of the helicase.

主权项

1. A pharmaceutical composition comprising a compound of formula I: or a pharmaceutically acceptable salt thereof; and one or more pharmaceutically acceptable excipients or carriers, wherein the excipient or carrier is selected from the group consisting of an ion exchanger, alumina, aluminum stearate, lecithin, a serum protein, human serum albumin, phosphate, glycine, sorbic acid, potassium sorbate, vegetable fatty acids, protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, a zinc salt, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, cellulose, polyethylene glycol, sodium carboxymethylcellulose, polyacrylates, wax, polyethylene-polyoxypropylene-block polymer, polyethylene glycol, wool fat, lactose, dried corn starch, Ringer's solution, dextrose, Hank's solution, ethyl oleate, isopropyl myristate, sucrose, sorbitol, mannitol, gum acacia, calcium phosphate, mineral oil, cocoa butter, oil of theobroma, alginates, tragacanth, gelatin, methylcellulose, polyoxyethylene, sorbitan monolaurate, methyl hydroxybenzoate, propyl hydroxybenzoate, talc and magnesium stearate, alcohol, mineral oil, petrolatum, propylene glycol, polyoxyethylene, and polyoxypropylene.